Four new medicines introduced in January
Includes new medicines for HIV and chronic kidney disease
Four new medicines have been accepted for use on in England this month, including new generics for hypertension and Alzheimer’s disease.
A new generic form of telmisartan 40mg /hydrochlorothiazide 12.5mg (Micardis Plus) has been approved under the brand name Actelsar for use in hypertension patients not adequately controlled by telmisartan alone.
There is also a new generic extended release form of Alzheimer’s treatment galantamine hydrobromide (Reminyl XL), under the product name Gazylan XL, and comes in 8mg, 16mg and 24mg doses. The drug is indicated for mild to moderately severe Alzheimer’s dementia.
A new combination antiviral HIV therapy has been launched: darunavir 800mg/cobicistat 150mg (Rezolsta). The treatment is a protease inhibitor and pharmacoenhancing agent that increases systemic levels of co-administered agents that are metabolised by CYP3A.
The treatment is used in combination with other antiretrovirals for HIV-1 infection in adults aged 18 years or older.
And finally sucroferric oxyhydroxide (Velphoro) is indicated for the control of serum phosphorus levels in adult chronic kidney disease patients on haemodialysis or peritoneal dialysis.
Its licence notes that it should be used within the context of a multiple therapeutic approach, which could include calcium supplement, 1,25-dihydroxy vitamin D3 or one of its analogues, or calcimimetics to control the development of renal bone disease.